CLNN250117P3000
- 2.60
- 0.000.00%
Clene Newsroom
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital
Clene Is Maintained at Buy by D. Boral Capital
Clene Analyst Ratings
Benchmark Maintains Buy on Clene, Lowers Price Target to $84
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital
Clene Is Maintained at Buy by D. Boral Capital
Clene Analyst Ratings
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Clene's Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic Developments
Clene Price Target Maintained With a $23.00/Share by EF Hutton
Clene Is Maintained at Buy by EF Hutton
Clene Analyst Ratings
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Strategic Advancements and Robust Trial Design Drive Buy Rating for Clene
Benchmark Co. Sticks to Their Buy Rating for Clene (CLNN)
Clene Is Maintained at Buy by EF Hutton
Clene Price Target Maintained With a $23.00/Share by EF Hutton
Clene Analyst Ratings